Abstract:The Cancer Genome Atlas (TCGA) consortium measured genome-wide gene expression using RNA-seq for 336 skin cutaneous melanoma (SKCM) samples among which 272 were clinically classified as metastatic SKCM tumors and the remaining 64 as primary SKCM tumors. We aimed to identify gene signatures that separate the primary SKCM from the metastatic SKCM samples. Our initial analysis showed that the primary and metastatic SKCM samples shared enough similarity at the gene expression level so that misclassification rates were unacceptably high. We reasoned that some of the primary SKCM tumors plausibly might have evolved to resemble the metastatic tumors in their gene expression. This idea led us to propose an alternative computational method to find a gene signature for accurate classification but does so while making explicit allowance for allegiance switching moving samples from one group to the other, e.g., primary to metastatic or vice versa. Based on an iterative stochastic search algorithm that delivers nearly optimal gene signatures for classification, our alternative algorithm is rooted in the groups defined by clinical classification but allows for switching between groups when a sample is clearly discordant with other group members based on its gene expression profile. We began by seeking such near-optimal partitioning of the 336 samples into the primary and metastatic groups based on the gene expression data using the clinical classification as the guide/basis. Specifically, our algorithm gives each of the 336 samples a small but equal probability to be switched to the other group at each iteration (e.g., from metastatic to primary, or vice versa). We carried out a massive computational search for gene signatures (a set of 20 genes) that provide a near optimal partitioning of the groups while keeping the clinical classification for most of the 336 samples but reassigning a few to the other group. Distinguishing between the newly re-assigned primary and metastatic partitioning now possible based on gene expression data. The search carried out 5,000 independent runs of our alternative stochastic search algorithm to generate 5,000 near-optimal gene signatures and 5,000 sets of near-optimal partitioning of the groups. By examining how often a sample was assigned to the primary and metastatic groups, we could estimate the proportion of runs where the sample was classified as a primary or metastatic SKCM tumor. We found that nearly all the clinically classified metastatic tumors were consistently assigned to the metastatic tumor group in 90-100% of the runs whereas the clinically classified primary SKCM tumors were often reassigned to the metastatic tumor group in proportions ranging from 2% to 80%. This result suggests that the gene expression profiles of many primary tumors resemble those of metastatic tumors to various degrees. Gene ontology analysis of the 500 most frequently selected genes (those appearing most frequently in the 5,000 gene signatures) suggested that the top-ranked genes are enriched in ectoderm and epidermis development, epithelia and epidermal cell differentiation, kerationization, and regulation of inflammatory and defense response. In summary, we have developed a unique computational method that not only assesses the relevance of genes in sample classification but also classifies each sample probabilistically to uncover the true tumor status. Our analysis may provide useful information for treatment and disease management. Citation Format: Yuanyuan Li, Juno Krahn, Leping Li. Assessing the similarity and dissimilarity between primary and metastatic melanoma using gene expression data. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Melanoma: From Biology to Therapy; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(14 Suppl):Abstract nr A17.

Gene Expression Difference Between Primary and Metastatic Renal Cell Carcinoma Using Patient-Derived Xenografts

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Differential Response to EGFR- and VEGF-targeted Therapies in Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma and Related Metastases

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

Primary Tumor Site Specificity is Preserved in Patient-Derived Tumor Xenograft Models

Metabolic Difference Between Patient-Derived Xenograft Model of Pancreatic Ductal Adenocarcinoma and Corresponding Primary Tumor

An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study

Establishment of Pancreatic Cancer Patient-Derived Xenograft Models and Comparison of the Differences among the Generations.

Patient-derived Non-Small Cell Lung Cancer Xenograft Mirrors Complex Tumor Heterogeneity.

Identification of Differentially Expressed Genes Between Original Breast Cancer and Xenograft Using Machine Learning Algorithms

Multilayered Molecular Profiling Supported the Monoclonal Origin of Metastatic Renal Cell Carcinoma.

Differential Expressions of PD-1, PD-L1 and PD-L2 Between Primary and Metastatic Sites in Renal Cell Carcinoma

Assessing The Similarity And Dissimilarity Between Primary And Metastatic Melanoma Using Gene Expression Data

Intra-tumour Molecular Heterogeneity of Clear Cell Renal Cell Carcinoma Reveals the Diversity of the Response to Targeted Therapies Using Patient-Derived Xenograft Models.

Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis

Histologic and Molecular Analysis of Patient Derived Xenografts of High-Grade Serous Ovarian Carcinoma

Immunohistochemical Analysis of Primary Renal Cell Carcinomas and Paired Bone Metastases

Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior

Global Analysis of Metastasis-Associated Gene Expression in Primary Cultures from Clinical Specimens of Clear-Cell Renal-Cell Carcinoma